{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '33.', 'Vaccines Licensed for Use in the United States U.S. Food and Drug Administration.', '(https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-', 'states).', '34.', 'Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, Group QHDS. Safety and', 'immunogenicity of high-dose quadrivalent influenza vaccine in adults >/=65years of age:', 'A phase 3 randomized clinical trial. Vaccine 2019;37(39):5825-5834.DOI:', '10.1016/j.vaccine.2019.08.016', '35.', 'Brazier J, Jones N, Kind P. Testing the validity of the Euroqol and comparing it with the', 'SF-36 health survey questionnaire. Qual Life Res 1993;2(3):169-80 DOI:', '10.1007/BF00435221.', '36.', 'Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new', 'five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20(10):1727-36. DOI:', '10.1007/s11136-011-9903-X.', '37.', 'van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the', 'EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15(5):708-15.DOI:', '10.1016/j.jval.2012.02.008.', '38.', 'Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring', 'for the SF-12 Health Survey in nine countries: results from the IQOLA Project.', 'International Quality of Life Assessment. J Clin Epidemiol 1998;51(11):1171-8.DOI:', '10.1016/s0895-4356(98)00109-7.', '39.', 'Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of', 'scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220-33. DOI:', '0.1097/00005650-199603000-00003', '40.', 'Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and', 'vaccine evaluation. Expert Rev Anti Infect Ther 2011;9(6):669-83. DOI:', '10.1586/eri.11.5', '41.', 'Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell', 'responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture', 'in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol', '2004;172(6):3437-46. (https://www.ncbi.nlm.nih.gov/pubmed/15004143)', '42.', 'Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and', 'immunologic predictors of influenza illness among vaccinated older adults. Vaccine', '2010;28(38):6145-51. DOI: 10.1016/j.vaccine.2010.07.036.', '43.', 'Kwong JC, Vasa PP, Campitelli MA, et al. Risk of Guillain-Barre syndrome after', 'seasonal influenza vaccination and influenza health-care encounters: a self-controlled', 'study. Lancet Infect Dis 2013;13(9):769-76. DOI: 10.1016/S1473-3099(13)70104-X', '44.', 'McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in', 'children and adults. J Allergy Clin Immunol 2016;137(3):868-78. DOI:', '10.1016/j.jaci.2015.07.048.', '57']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, , 2021', 'APPENDIX', 'Appendix A: EQ-5D-5L and VAS', 'Appendix B: Corticosteroid Dose Charts', '58']\n\n###\n\n", "completion": "END"}